Featured News: Stalicla licensing deal

Evgen Pharma has licensed the global rights for lead asset SFX‐01 in neurodevelopmental disorders and schizophrenia to Stalicla Read More
Filter by:

Regulatory News

Media Coverage

Videos

down chevron